IFW

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/687,996
Filing Date	October 17, 2003
First Named Inventor	Lothar Steidler
Art Unit	1652
Examiner Name	E. Slobodyansky
Attorney Docket Number	2676-6096US

Total Number of Pages in This Submission

ENCLOSURES *(check all that apply)*

☐ Fee Transmittal Form
  ☐ Fee Attached
☐ Amendment / Reply
  ☐ After Final
  ☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☐ Information Disclosure Statement
☒ Certified Copy of Priority Document(s)
☐ Reply to Missing Parts/ Incomplete Application
  ☐ Reply to Missing Parts under 37 CFR1.52 or 1.53

☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____
  ☐ Landscape Table on CD

☐ After Allowance Communication to TC
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☐ Other Enclosure(s) *(please identify below)*:

Remarks

The Commissioner is authorized to charge any additional fees required but not submitted with any document or request requiring fee payment under 37 C.F.R. §§ 1.16 AND 1.17 TO Deposit Account 20-1469 during pendency of this application.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	TraskBritt, P.C.
Signature	
Printed Name	Allen C. Turner
Date	August 16, 2006
Reg. No.	33,041

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Denise Dyer	Date	August 16, 2006

Europäisches Patentamt GD1	European Patent Office DG1	Office européen des brevets DG1

Bescheinigung	Certificate	Attestation
Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.	The attached documents are exact copies of the European patent application described on the following page, as originally filed.	Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécificée à la page suivante.

Patentanmeldung Nr.	Patent application No.	Demande de brevet n°

01201631.7 / EP01201631

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP01201631

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le President de l'Office européen des brevets
p.o.

R.C. van Dijk

CV01387

Anmeldung Nr:
Application no.:   01201631.7
Demande no:

Anmeldetag:
Date of filing: 03.05.01
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor
Biotechnologie vzw.
Rijvisschestraat 120
9052 Zwijnaarde/BE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Self-containing lactococcus strain

In anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation / International Patent Classification / Classification internationale de brevets:

C12N1/00

Am Anmeldetag benannte Vertragstaaten / Contracting states designated at date of filing / Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

SELF-CONTAINING *Lactococcus* STRAIN

The invention relates to a recombinant *Lactococcus* strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant *Lactococcus*
5   that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a *Lactococcus* that may only survive in a host organism, where said medium compounds are present, but cannot survive outside the host organism in absence of said medium compounds.

Lactic acid bacteria have long time been used in a wide variety of industrial
10   fermentation processes. They have generally-regarded-as-safe status, making them potentially useful organisms for the production of commercially important proteins. Indeed, several heterologous proteins, such as Interleukin-2, have been succesfully produced in *Lactococcus* spp (Steidler *et al.*, 1995). It is, however, unwanted that such genetically modified microorganisms are surviving and spreading in the
15   environment.

To avoid unintentional release of genetically modified microorganisms, special guidelines for safe handling and technical requirements for physical containment are used. Although this may be useful in industrial fermentations, the physical containment is generally not considered as sufficient, and additional biological
20   containment measures are taken to reduce the possibility of survival of the genetically modified microorganism in the environment. Biological containment is extremely important in cases where physical containment is is difficult or even not applicable. This is, amongst others, the case in applications where genetically modified microorganisms are used as live vaccines or as vehicle for delivery of therapeutical
25   compounds. Such applications have been described e.g. in WO 97/14806, which discloses the delivery of biologically active peptides, such as cytokines, to a subject, by recombinant non-invasive or non-pathogenic bacteria. WO 96/11277 describes the delivery of therapeutic compounds to an animal – including humans - by administration of a recombinant bacterium, encoding the therapeutic protein. Steidler
30   *et al.* (2000) describe the treatment of colitis by administration of a recombinant *Lactococcus lactis*, secreting interleukin-10. Such a delivery may indeed be extremely useful to treat a disease in an affected human or animal, but the recombinant bacterium may act as a harmful and pathogenic microorganism when it enters a non-

1

affected subject, and an efficient biological containment that avoids such unintentional spreading of the microorganism is needed.

Biological containment systems for host organisms may be passive, based on a strict requirement of the host for specific growth factor or a nutrient, that is not present or

5   pesent in low concentrations in the outside environment, or active, based on so-called suicidal genetic elements in the host, whereby the host is killed in the outside environment by a cell killing function, encoded by a gene that is under control of a promoter only being expressed under specific environmental conditions.

Passive biological containment systems are well known in mircoorganisms such as

10   Escherichia coli or Saccharomyces cerevisiae. Such E. coli strains are disclosed e.g. in US4100495. WO 95/1061 discloses lactic acid bacterial suppressor mutants and their use as means of containment in lactic acid bacteria, but in that case, the containment is on the level of the plasmid, rather than on the level of the host strain and it stabilizes the plasmid in the host strain, but doesn't provide containment for the

15   genetically modified host strain itself.

Active suicidal systems have been described by several authors. Such system consists of two elements: a lethal gene, and a control sequence that switches on the expression of the lethal gene under non-permissive conditions. WO 95/10614 discloses the use of a cytoplasmatically active truncated and/or mutated

20   Staphylococcus aureus nuclease as lethal gene. WO 96/40947 discloses a recombinant bacterial system with environmentally limited viability, based on the expression of either an essential gene, expressed when the cell is in the permissive environment and is not expressed or temporarily expressed when the cell is in the non-permissive environment and/or a lethal gene, wherein expression of the gene is

25   lethal to the cell and the lethal gene is expressed when the cell is in the non-permissive environment but not when the cell is in the permissive environment. WO 99/58652 describes a biological containment system based on the relE cytotoxin. However, most systems have been elaborated for Escherichia coli (Tedkin et al., 1995; Knudsen et al., 1995; Schweder et al., 1995) or for Pseudomonas (Kaplan et al.,

30   1999; Molino et al., 1998). Although several of the containment systems theoretically can by applied to lactic acid bacteria, no specific biological containment sytems for Lactococcus have been described.

It is the objective of the present invention to provide a suitable biological containment system for Lactococcus.

2

A first aspect of the invention is an isolated strain of *Lactococcus* sp. comprising a defective thymidylate synthase gene. Preferrably, said defective thymidylate synthase gene is inactivated by gene disruption. Even more preferrably, said *Lactococcus* sp. is *Lactococcus lactis*. A special embodiment is a *Lactococcus* sp. strain, preferably

5 *Lactococcus lactis*, more preferrably a *Lactococcus lactis* MG1363 derivative, whereby the thymidylate synthase gene has been disrupted and replaced by and replaced by a human interleukin-10 expression unit.

Another aspect of the invention is the use of a strain according to the invention as host strain for transformation, whereby the transforming plasmid does not comprise

10 an intact thymidylate synthase gene.

Still another aspect of the invention is a transformed strain of *Lactococcus* sp. according to the invention, comprising a plasmid that does not comprise an intact thymidylate synthase gene.

Another aspect of the invention is a medical preparation, comprising a transformed

15 strain of *Lactococcus* sp., according to the invention.

The *Lactococcus lactis* subsp. *lactis* thymidylate synthase gene (*thyA*) has been cloned by Ross *et al.* (1990a); it sequence is comprised in SEQ ID N° 3. EP0406003 discloses a vector devoid of antibiotic resistance and bearing a thymidylate synthase gene as a selection marker; the same vector has been described by Ross *et al.*

20 (1990b). However, although it would have been logical to use this vector in a *Lactococcus lactis* strain, this has not been realized due to the lack of a suitable *thyA* mutant. Indeed, such a mutant has never been described. Surprisingly, we were able to construct such mutant by gene disruption, using homologous recombination in *Lactococcus*. In a preferred embodiment, the *thyA* gene is disrupted by a functional

25 human interleukin-10 expression cassette. However, it is clear that any construct can be used for gene disruption, as long as it results in an inactivation of the *thyA* gene or in an inactive thymidylate synthase. As a non-limiting example, the homologous recombination may result in a deletion of the gene, in one or more amino acid substitutions that lead to an inactive form of the tymidylate synthase, or to a frameshift

30 mutation resulting in a truncated form of the protein.

Such a *Lactococcus* sp. *thyA* mutant is very useful as a host strain for transformation, in situations where more severe containment than purely physical containment is needed. Indeed, it is known that *thyA* mutants cannot survive in an environment without, or with only a limited concentration of thymidine and/or thymine. When such a

strain is transformed with a plasmid that doesn't comprise an intact *thyA* gene and cannot complement the mutation, the transformed strain will become suicidal in a thymidine/thymine poor environment. Such a strain can be used in a fermentor, as an additional protection for the physical containment, but is especially useful in cases where the strain is used as a delivery vehicle in an animal body. Indeed, when such a transformed strain is given orally to an animal – including humans – it will survive in the gut, provided a sufficiently high concentration of thymidine/thymine is present, and will produce homologous and/or heterologous proteins that may be beneficial for said animal. However, once said strain is secreted in the environment, e.g. in the faeces, it will not be able to survive any longer.

The transforming plasmid can be any plasmid, as long as it cannot complement the *thyA* mutation. It may be a selfreplicating plasmid that preferably carries one or more genes of interest and one or more resistance markers, or it may be an integrative plasmid. In the latter case, the integrative plasmid itself may be used to create the mutation, by causing integration at the *thyA* site, whereby the *thyA* gene is inactivated. Preferably, the active *thyA* gene is replaced by double homologous recombination by a casette comprising the gene or genes of interest, flanked by targetting sequences that target the insertion to the *thyA* target site. It is of extreme importance that these sequences are sufficiently long and sufficiently homologous to obtain to integrate the sequence into the target site. Preferably, said targetting sequences consist of at least 100 contiguous nucleotides of SEQ ID N°1 at one side of the gene of interest, and at least 100 contiguous nucleotides of SEQ ID N°2 at the other side; more preferably, said targetting sequences consists of at least 500 contiguous nucleotides of SEQ ID N°1 at one side of the gene of interest, and at least 500 contiguous nucleotides of the SEQ ID N° 2 at the other side; most preferably, said targetting sequences consists of SEQ ID N°1 at one side of the gene of interest and SEQ ID N°2 at the other side, or said targetting sequences consist of at least 100 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 1 at one side of the gene of interest, and of at least 100 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 2 at the other side of the gene of interest, preferably said targetting sequences consist of at least 500 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 1 at one side of the gene of interest, and of at least 500 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 2 at the other side of the gene of

interest, most preferably said targetting sequences consist of at least 1000 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 1 at one side of the gene of interest,and of at least 1000 nucleotides that are at least 80% identical, preferably 90% identical to a region of SEQ ID N° 2 at the

5   other side of the gene of interest . The percentage identity is measured with BLAST, according to Altschul *et al.* (1997).

Transformation methods of *Lactococcus* are known to the person skilled in the art, and include, but are not limited to protoplast transformation and electroporation.

A transformed *Lactococcus* sp. strain according to the invention is useful for the

10   delivery of prophylactic and/or therapeutical molecules and can be used in a pharmaceutical composition. The delivery of such molecules has been disclosed, as a non-limiting example, in WO 97/14806 and in WO 98/31786. Prophylactic and/or therapeutical molecules include, but are not limited to polypetides such as insuline, growth hormone, prolactine, calcitonin, group 1 cytokines, group 2 cytokines and

15   group 3 cytokines and polysaccharides such as polysaccharide antigens from pathogenic bacteria. A preferred embodiment is the use of a *Lactococcus* sp. strain according to the invention to deliver human interleukin-10. This strain can be used in the manufacture of a medicament to treat Crohn's disease.

20   **Brief description of the figures**

Figure 1: Map of the MG1363 *thyA* locus

Figure 2: Schematic representation of *thyA* loci of genetically engineered *thyA* negative *L. lactis* strains containing different hIL-10 expression units. Black parts

25   represent original *L. lactis* MG1363 genetic information, white parts represent recombinant genetic information.

Examples

From L. lactis MG1363 (Gasson, 1983) we have cloned out the regions flanking the

30   sequence according to Ross *et al.* (1990a)

The knowledge of these sequences is of critical importance for the genetic engineering of any lactococcus strain in a way as described below, as the strategy will employ double homologous recombination in the areas 1000 bp at the 5'end (SEQ ID N°1) and 1000 bp at the 3'end (SEQ ID N°2) of thyA, the "thyA target". These

sequences are not available from any public source to date. We have cloned these flanking DNA fragments and have identified their sequence. The sequence of the whole locus is shown in SEQ ID N°3. Both the 5' and 3' sequences are different from the sequence at genbank AE006385 describing the *L. lactis* IL1403 sequence (Bolotin,

5   in press) or at AF336368 describing the *L. lactis* subsp. *lactis* CHCC373 sequence. From the literature it is obvious that homologous recombination by use of the published sequences adjacent to *thyA* (Ross *et al.*, 1990a) (86 bp at the 5'end and 31 bp at the 3'end) is virtually impossible due to the shortness of the sequences. Indeed, Biswas *et al.* (1993) describe a logarithmically decreasing correlation between length

10 of the homologous sequences and frequency of integration.

The *thyA* replacement is performed by making suitable replacements in a plasmid borne version of the *thyA* target, as described below. The carrier plasmid is a derivative of pORI19 (Law *et al.*, 1995) a replication defective plasmid, which only transfers the erythromycin resistance to a given strain when a first homologous

15 recombination, at either the 5' 1000bp or at the 3'1000bp of the *thyA* target. A second homologous recombination at the 3' 1000bp or at the 5' 1000bp of the *thyA* target yields the desired strain.

The *thyA* gene is replaced by a synthetic gene encoding a protein which has the *L. lactis* Usp45 secretion leader (van Asseldonk *et al.*, 1990) fused to a protein of

20 identical amino acid sequence than: (a) the mature part of human-interleukin 10 (hIL-10) or (b) the mature part of hIL-10 in which proline at position 2 had been replaced with alanine or (c) the mature part of hIL-10 in which the first two amino acids had been deleted; (a), (b) and (c) are called hIL-10 analogs, the fusion products are called Usp45-hIL-10.

25 The *thyA* gene is replaced by an expression unit comprising the lactococcal P1 promotor (Waterfield *et al.*, 1995), the *E. coli* bacteriophageT7 expression signals: putative RNA stabilising sequence and modified gene10 ribosomal binding site (Wells and Schofield, 1996).

At the 5' end the insertion is performed in such way that the ATG of thyA is fused to

30 the P1-T7Usp45-hIL-10 expression unit.

```
5'agataggaaaatttcatgacttacgcagatcaagttttt...thyA wild type
                gattaagtcatcttacctctt...P1-T7-usp45-hILl0
5'agataggaaaatttcatggattaagtcatcttacctctt...thyA⁻,P1-T7-usp45-
hILl0
```

Alternatively, at the 5' end the insertion is performed in such way that the thyA ATG is not included:

```
5'agataggaaaatttcacttacgcagatcaagttttt...thyA wild type
```

5
```
                        gattaagtcatcttacctctt...P1-T7-usp45-hIL10
5'agataggaaaatttcgattaagtcatcttacctctt...thyA⁻,P1-T7-usp45-
hIL10
```

Alternatively, at the 5' end the insertion is performed in such way that the thyA

10 promotor [Ross, 1990 a] is not included:
```
5'tctgagaggttattttgggaaatactattgaaccatatcgaggtgtgtggtataatgaagg
gaattaaaaaagataggaaaatttcatg...thyA wild type
```

```
                                     gattaagtcatcttacctctt...P1-T7-
```
15
```
usp45-hIL10
5'tctgagaggttattttgggaaatactagattaagtcatcttacctctt...thyA⁻,P1-
T7-usp45-hIL10
```

At the 3' end an ACTAGT SpeI restriction site was engineered immediately adjacent

20 to the TAA stop codon of the usp45-hIL-10 sequence. This was ligated in a TCTAGA *Xbal* restriction site, which was engineered immediately following the thyA stop codon

```
aaaatccgtaactaactagt3'...usp45-hIL10
gatttagcaatttaaattaaattaatctataagtt3'...thyA-wild type
```
25
```
            tctagaattaatctataagttactga3'...engineered thyA target
aaaatccgtaactaactagaattaatctataagttactga3'...thyA⁻,usp45-hIL10
```

These constructs are depicted in figure 2

The resulting strain is *thyA* deficient, a mutant not yet described for *L. lactis*. It is strictly dependent upon the addition of thymine or thymidine for growth.

30

References

- Altschul, S. F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W. and Lipman D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* **25**, 3389 – 3402.

- Biswas, I., Gruss, A., Ehrlich, S.D. et al. (1993) High-efficiency gene inactivation and replacement system for gram- positive bacteria. *J. Bacteriol.* **175**, 3628 – 3635.

- Gasson, M. J. (1983). Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. *J. Bacteriol.* **154**, 1 – 9.

- Kaplan, D.L., Mello, C., Sano, T., Cantor, C. and Smith, C. (1999). Streptavadin-based containment system for genetically engineered microorganisms. *Biomol. Eng.* **31**, 135 – 140.

- Knudsen, S., Saadbye, P., Hansen, L.H., Collier, A., Jacobsen, B.L., Schlundt, J. And Karlstrom, O.H. (1995). Development and testing of improved suicide functions for biological containment of bacteria. *Appl. Environ. Microbiol.* **61**, 985 – 991.

- Law, J., Buist, G., Haandrikman, A. et al. (1995). A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. *J. Bacteriol.* **177**, 7011 – 7018.

- Molina, L., Ramos, C., Ronchel, M.C., Molin, S. and Ramos, J.L. (1998). Construction of an efficient biologically contained pseudomonas putida strain and its survival in outdoor assays. *Appl. Environ. Microbiol.* **64**, 2072 – 2078.

- Ross, P., O'Gara, F. and Condon, S. (1990a). Cloning and characterization of the thymidylate synthase gene from *Lactococcus lactis* subsp. *Lactis*. *Appl. Environ. Microbiol.* **56**, 2156-2163.

- Ross, P., O'Gara, F. and Condon, S. (1990b). Thymidylate synthase gene from *Lactococcus lactis* as a genetic marker: an alternative to antibiotic resistance. *Appl. Environ. Microbiol.* **56**, 2164-2169.

- Schweder, T., Hofmann, K. And Hecker, M. (1995). *Escherichia coli* K12 relA strains as safe hosts for expression of recombinant DNA. *Appl. Environ. Microbiol.* **42**, 718 – 723.

- Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fier, W. and Remaut, E. (2000). Treatment of murine colitis by *Lactococcus lactis* secreting Interleukin-10. *Science* **289**, 1352 – 1355.

- Steidler, L., Wells, J.M., Raeymaekers, A., Vandekerckhove, J., Fiers, W. And Remaut, E. (1995). Secretion of biologically active murine Interleukin-2 by *Lactococcus lactis* subsp. *Lactis*. *Appl. Environ. Microbiol.* **61**, 1627-1629.

- Tedin, K. Witte, A., Reisinger, G., Lubitz, W. and Basi, U. (1995). Evaluation of the *E. coli* ribosomal rrnB P1 promoter and phage derived lysis genes for the use in biological containment system: a concept study. *J. Biotechnol.* **39**, 137 – 148.

5   - van Asseldonk, M., Rutten, G., Oteman, M. et al. (1990). Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. *Gene* **95**, 155 – 160.

- Waterfield, N.R., Le Page, R.W., Wilson, P.W. et al. (1995) The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis. *Gene* **165**,9 – 15.

10   - Wells, J.M. and Schofield, K.M. (1996) Cloning and expression vectors for Lactococci. *Nato ASI series* H **98**, 37 – 62.

Claims

1. An isolated strain of *Lactococcus* sp. comprising a defective thymidylate synthase gene.

2. A strain of *Lactococcus* sp. according to claim 1, whereby said gene is inactivated by gene disruption.

3. An isolated strain of *Lactococcus* sp. according to claim 1 or 2, whereby said *Lactococcus* sp. is *Lactococcus lactis*.

4. The use of a strain of *Lactococcus* sp. according to any of the claims 1-3 as host strain for transformation, whereby the transforming plasmid does not comprise an intact thymidylate synthase gene.

5. A transformed strain of *Lactococcus* sp. according to any of the claims 1-3, comprising a transforming plasmid that does not comprise an intact thymidylate synthase gene.

6. A pharmaceutical composition comprising a transformed strain of *Lactococcus* sp. according to claim 5

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnol

<120> Self-containing Lactococcus strain

<130> LS/ThyA/085

<140>
<141>

<160> 4

<170> PatentIn Ver. 2.1

<210> 1
<211> 1000
<212> DNA
<213> Lactococcus lactis

<400> 1
tatatacaat tgagcaaaag aaatttagtt attaaattac cagctggagt tcctccaatg 60
gttgtagatt cactaagtcc agcaattatt tcaatggtga ttttctgttt gatgttcggg 120
attcgtgtgg gattctctta tacgccattc catgatattt tcaatttctc aacacaacta 180
attcaagcac cgttgactgg tgctgtggca aatccatggg ttcttatggg catctttacc 240
tttggtaatt tcttatggtt ctttggtatc caccctaatt taattggggg aattttaaat 300
ccattgttat taacaatgtc atatgctaat attgatgcct atgctgccgg aaaacctgta 360
ccatacttac aaatgatgat tgtgtttgct gtgggtgcga acgcatgggg cggaagtgga 420
aatacttatg ggttagttat ttcaatgttt acggcaaaat ctgaacgcta taaacaatta 480
ttaaaattag gtgcaattcc tagtattttc aatatcagtg aaccattact ttttggtctt 540
ccaatgatgt taaatcctct tttctttatt cctttggttt tccaaccagc aattttagga 600
actgtagcat tgggcttggc aaagatatta tatattacaa atctgaatcc aatgacggca 660
cttcttcctt ggacgacacc agcacctgtg agaatggcca tttcaggtgg acttccattt 720
ttgattattt ttgcaatctg tttagtcttg aatgttctta tttactaccc attctttaag 780
gtggcgtata ataaagcttt agaagaagaa aaagcagctg ttgaattaga gggttcagaa 840
actgcctgat ggatattttt tataaatctg gtttgaacaa attatattga catctctttt 900
tctatcctga taattctgag aggttatttt gggaaatact attgaaccat atcgaggtgt 960
gtggtataat gaagggaatt aaaaaagata ggaaaatttc   1000

<210> 2
<211> 1000
<212> DNA
<213> Lactococcus lactis

<400> 2
taaattaatc tataagttac tgacaaaact gtcagtaact ttttttgtgg gaaaaatgta 60
tttttatgac cgtaaagaat ctgtcagtag aagtctgaaa ttcgtttaaa aatcgactag 120

1

+0031703404699   03 MEI'2001 16:58 ONTVANGEN VAN   +0092446610   #5176 000

```
aataggcttt aacgacaaga tgttttaaag agtacgctct aaatgtattt ttgtattttt 180
gtttgattac gaagtttaaa tttaattgac aaatgtttta aaatgagtat aataggactt 240
gtaaccgatt ttatttttat aaaggagaaa gaaagatgaa caaactttta cttggaacag 300
cctttatagg ggctagctta ctgattggtg ggggtgctca tgcagatcaa atgtttatcg 360
tttgtataat cataatactg gtgagcactc tatacaacta gtgggacacc aaaagaatgc 420
taatgtaagt gcgggttgga cttatgaagg tgtcggttgg atcgcaccaa caacaagttc 480
aagcccagtt taccgtgtgt acaatccaaa tgcattatta cacaaaaagc aagtatgaag 540
cccaaagttt agtaaataag ggttggaaat gggataataa cggaaaggcg gtcttctatt 600
ctggaggttc tcaagccgta tatgtcgctt ataatcccaa tgcacaatct ggcgctcaca 660
attacacgga aagtagcttt gagcaaaata gcttattgaa tactggttgg aaatatgggg 720
cagtagcttg gtacgggatt ggagtaaaaa acgaaatgtt aaacattgct caaattgtta 780
gtggtaattt ttctagtatt gttggaactt ggaaagatac ttctggaaat atgcttgaaa 840
ttaatgcaat gggaaatctt actttaatat ggaaaggggc aaagaatcaa acctttgaac 900
ttggcgcagg tcaacaattt aatggaactg cagatattgc cttaaaaaat ggagagattt 960
cccctggtag tccacttaac atttttgttg taccaacaga                         1000
```

```
<210> 3
<211> 7157
<212> DNA
<213> Lactococcus lactis

<220>
<221> CDS
<222> (4473)..(5312)

<400> 3
gnagnggttt tcccagtccg acgttgtaaa acgacggcca gtgaattcat taacagcctt 60

ttgagcagct agctcattat tttgaaataa atcataaatt tctttcccac tatctgattt 120

atgattgcta gcatatttgt tgtataatcg aacgagtcca ttttgaacag atccatatag 180

attgagtgaa ctataaaata catctatatc atagttgagt ttgttcacaa tcatgagacc 240

aaattctcca gcatttcgtg tagaaccacg ataaagctgt ttatttagca aaatggcacc 300

tccgacacct gtacctaaag tcatgcaaat aaaatttgg ctttcttgtc cattccctag 360

ccaaagttca gctagacctg cacaattggc atcattttca acataaaccg gaagatttaa 420

atgttttgt agttctgtcc ccaatggata gccataaaga tcagttagag ctcctgccag 480

taataatgtt ccctttttgt cagaagttcc gggaacactt acaccaattg cagatactga 540

atgatgagct tttaactgat gaatatttgt gagcaagcta tccataattt ttcttttt 600

taatggggtt ggaacttgta aatgttgtat gatcgttcca tcactagtta caagaccaaa 660
```

2

```
ttttataaat gtaccaccga tatcaattcc tattgaataa tgcatctttt attacctctt 720

tctctaattt gttttagtat agcaaaatca aaaaattaat tatggtatgc attatagata 780

tgttgtataa ttttcacaaa aacggagaaa actatgaaaa caatagaaca gctcatgata 840

gattcagcag atttaatgtc agattttatt caattgacaa ttttatatt ccgcaaggag 900

gattttcaac tttttatag gagtgatgaa gaagagcaag cttttcaag gtaatgactc 960

caacttattg atagtgtttt atgttcagat aatgcccgat gactttgtca tgcagctcca 1020

ccgattttga gaacgacagc gacttccgtc ccagccgtgc caggtgctgc ctcagattca 1080

ggttatgccg ctcaattcgc tgcgtatatc gcttgctgat tacgtgcagc tttcccttca 1140

ggcgggattc atacagcggc cagccatccg tcatccatat caccacgtca aagggtgaca 1200

gcaggctcat aagacgcccc agcgtcgcca tagtgcgttc accgaatacg tgcgcaacaa 1260

ccgtcttccg gagactgtca tacgcgtaaa acagccagcg ctggcgcgat ttagccccga 1320

catagcccca ctgttcgtcc atttccgcgc agacgatgac gtcactgccc ggctgtatgc 1380

gcgaggttac cgactgcggc ctgagttttt taagtgacgt aaaatcgtgt tgaggccaac 1440

gcccataatg cgggctgttg cccggcatcc aacgccattc atggccatat caatgatttt 1500

ctggtgcgta ccgggttgag aagcggtgta agtgaactgc agttgccatg ttttacggca 1560

gtgagagcag agatagcgct gatgtccggc ggtgcttttg ccgttacgca ccaccccgtc 1620

agtagctgaa caggagggac agctgataga aacagaagcc actggagcac ctcaaaaaca 1680

ccatcataca ctaaatcagt aagttggcag catcaccctt tttcaaaaga aatcatcgct 1740

catttatctc agttgccctt gaaggaagag gtgaatttat tttatatgcc taagataaaa 1800

ggatatatta cttattttcc tgtatttggt aaagaggagt atcttctact tattttaaa 1860

ggacaagaaa aacttgcaaa taatcctttc cccgttgaag taaaacaatt attaaaaagt 1920

ggtattttac tctatcaaat gattttcaa gaaaaattag attatgaaga attatttgag 1980

aaaaatcagc atattatttc tccattgctt gctgctaaac caattgaatg gaatgattcc 2040

aatacgtgag gaaagtaaat tcccataaaa catatctttt tgaaaaatat ttggggggaat 2100
```

3

```
gtgttattcg  tggagatgtt  gcagagttaa  aaaaagcttt  ttcaaattat  atgaataaag  2160

gaactgctgg  aaaattatct  aataattcaa  tgcgacataa  gaaaaacatt  ttgatttcag  2220

tcatcactat  gactactcgt  tcggctatac  agggaggatt  acctgaagaa  gaagcttttt  2280

tgatgagtga  tttatatatt  caagagcttg  aagaactaac  ggaattagaa  gaaattagaa  2340

cgcttgccta  taatgtgatg  atcgattttg  cagataaagt  gaaacagcat  cgatattgtc  2400

aggtttctta  taaaatatta  tcttgtcaaa  agtatattgt  taatcattta  tacgaaaaac  2460

taagtgtgag  tgaaattgca  gaagagctac  acatgaatat  ttcttattta  tcttcacaat  2520

tcaaaaaga   gacagggcaa  acaattacaa  actttattca  ggagaagcga  atagaagaag  2580

ctagagaatt  aatccttttc  tcagactatc  ctttttcaag  aatttatacc  ttgttggttt  2640

tactgccaaa  gtcattttat  aaaaatattt  aaaaaatata  ctggaataac  tcccaaaaag  2700

tttcaagatc  agtatattta  tcatgcctct  acatcaatat  atgattgaaa  ttaaaaaaag  2760

acctagaatt  tcaaaattga  taaaatacat  acctaaaata  ttaattctgt  actattacgg  2820

gtggagtatc  tactgtataa  tgagggtata  aattatggaa  gaagggagta  aaactaaatt  2880

tattgatggt  tttacgaatt  aattaggata  ttttttttaa  aaaccaaaga  aaacgcttac  2940

aaacgttaaa  ggagtgaatc  taaagatgga  caaatttgaa  aaatggctaa  ataagacctt  3000

gatgccactt  gcctcaaaaa  tgaataaaaa  tcatttcatt  tcggcattaa  gtgaagcatt  3060

tatgagatgt  atgcccttaa  cattagggat  tgcattattg  acaattatag  gatactttcc  3120

agttcctgcc  tgggtagatt  tcttaaactc  tattggactg  gctcagcatt  tttcagcagt  3180

tattggtgca  gttaccagtg  cgctagcaat  ttatgtaact  tataattttg  cttattctta  3240

tgtaaatcgt  catgaatata  atggccatac  ggccggttta  ttatcaatcg  caagtttgtt  3300

aatgctaatg  ccacaaatta  ttactgtccc  tgtagtaaaa  aacattccaa  ccgaatttcc  3360

gaaatccgcg  gtagttgaca  gtgtgtcaaa  tgttgaagca  tttcaaacgg  tatacacggg  3420

tagcacagga  ttaattgtag  caatcataat  tggttttatt  gtttcattag  tctatataca  3480

attgagcaaa  agaaatttag  ttattaaatt  accagctgga  gttcctccaa  tggttgtaga  3540
```

4

```
ttcactaagt ccagcaatta tttcaatggt gattttctgt ttgatgttcg ggattcgtgt 3600

gggattctct tatacgccat tccatgatat tttcaatttc tcaacacaac taattcaagc 3660

accgttgact ggtgctgtgg caaatccatg ggttcttatg ggcatcttta cctttggtaa 3720

tttcttatgg ttctttggta tccaccctaa tttaattggg ggaattttaa atccattgtt 3780

attaacaatg tcatatgcta atattgatgc ctatgctgcc ggaaaacctg taccatactt 3840

acaaatgatg attgtgtttg ctgtgggtgc gaacgcatgg ggcggaagtg gaaatactta 3900

tgggttagtt atttcaatgt ttacggcaaa atctgaacgc tataaacaat tattaaaatt 3960

aggtgcaatt cctagtattt tcaatatcag tgaaccatta ctttttggtc ttccaatgat 4020

gttaaatcct cttttcttta ttcctttggt tttccaacca gcaattttag gaactgtagc 4080

attgggcttg gcaaagatat tatatattac aaatctgaat ccaatgacgg cacttcttcc 4140

ttggacgaca ccagcacctg tgagaatggc catttcaggt ggacttccat ttttgattat 4200

ttttgcaatc tgtttagtct tgaatgttct tatttactac ccattcttta aggtggcgta 4260

taataaagct ttagaagaag aaaaagcagc tgttgaatta gagggttcag aaactgcctg 4320

atggatattt tttataaatc tggtttgaac aaattatatt gacatctctt tttctatcct 4380

gataattctg agaggttatt ttgggaaata ctattgaacc atatcgaggt gtgtggtata 4440

atgaagggaa ttaaaaaaga taggaaaatt tc atg act tac gca gat caa gtt      4493
                                    Met Thr Tyr Ala Asp Gln Val
                                     1                   5

ttt aaa caa aat atc caa aat atc cta gat aat ggt gtt ttt tca gaa      4541
Phe Lys Gln Asn Ile Gln Asn Ile Leu Asp Asn Gly Val Phe Ser Glu
         10               15               20

aat gca aga cca aag tat aag gat ggt caa atg gcg aat agc aaa tat      4589
Asn Ala Arg Pro Lys Tyr Lys Asp Gly Gln Met Ala Asn Ser Lys Tyr
     25               30               35

gtc act ggt tca ttc gtt act tat gat ttg caa aag ggg gag ttt cca      4637
Val Thr Gly Ser Phe Val Thr Tyr Asp Leu Gln Lys Gly Glu Phe Pro
40               45               50               55

att acc act ttg cgt cca att cca atc aaa tct gct att aaa gaa ttg      4685
```

5

```
Ile Thr Thr Leu Arg Pro Ile Pro Ile Lys Ser Ala Ile Lys Glu Leu
            60              65                  70


atg tgg ata tac caa gac caa aca agt gaa ctt tct gtt ctc gaa gag    4733
Met Trp Ile Tyr Gln Asp Gln Thr Ser Glu Leu Ser Val Leu Glu Glu
            75              80                  85


aag tat gga gtc aaa tac tgg gga gaa tgg gga att ggt gat ggt acg    4781
Lys Tyr Gly Val Lys Tyr Trp Gly Glu Trp Gly Ile Gly Asp Gly Thr
            90              95                  100


att ggg caa cgt tat ggt gca aca gtc aaa aaa tat aat atc att ggt    4829
Ile Gly Gln Arg Tyr Gly Ala Thr Val Lys Lys Tyr Asn Ile Ile Gly
       105              110 .            115


aaa tta tta gaa ggc ttg gcc aaa aat cca tgg aat cgt cgt aat atc    4877
Lys Leu Leu Glu Gly Leu Ala Lys Asn Pro Trp Asn Arg Arg Asn Ile
120              125              130                  135


atc aac ctt tgg cag tat gaa gat ttt gag gaa aca gaa ggt ctt tta    4925
Ile Asn Leu Trp Gln Tyr Glu Asp Phe Glu Glu Thr Glu Gly Leu Leu
                 140              145              150


cca tgt gct ttc caa acg atg ttt gat gtc cgt cga gaa aaa gat ggt    4973
Pro Cys Ala Phe Gln Thr Met Phe Asp Val Arg Arg Glu Lys Asp Gly
                 155              160              165


cag att tat ttg gat gcc aca ctg att caa cgt tca aac gat atg ctt    5021
Gln Ile Tyr Leu Asp Ala Thr Leu Ile Gln Arg Ser Asn Asp Met Leu
            170              175              180


gta gcc cac cat atc aat gcg atg caa tat gtt gct ttg caa atg atg    5069
Val Ala His His Ile Asn Ala Met Gln Tyr Val Ala Leu Gln Met Met
       185              190              195


att gca aaa cat ttt tct tgg aaa gtt ggg aaa ttc ttt tat ttt gta    5117
Ile Ala Lys His Phe Ser Trp Lys Val Gly Lys Phe Phe Tyr Phe Val
200              205              210                  215


aat aat tta cat att tat gat aat cag ttt gag cag gca aat gaa tta    5165
Asn Asn Leu His Ile Tyr Asp Asn Gln Phe Glu Gln Ala Asn Glu Leu
                 220              225              230


atg aag cga aca gct tct gaa aaa gaa cct cgt ttg gtc ctt aat gtt    5213
Met Lys Arg Thr Ala Ser Glu Lys Glu Pro Arg Leu Val Leu Asn Val
            235              240              245


cct gat ggt aca aac ttt ttc gat att aaa cct gaa gat ttt gaa ctt    5261
```

6

```
      Pro Asp Gly Thr Asn Phe Phe Asp Ile Lys Pro Glu Asp Phe Glu Leu
              250                 255                 260


      gtg gac tat gag cca gta aaa cct caa ttg aaa ttt gat tta gca att      5309
      Val Asp Tyr Glu Pro Val Lys Pro Gln Leu Lys Phe Asp Leu Ala Ile
              265                 270                 275


      taa attaatctat aagttactga caaaactgtc agtaactttt tttgtgggaa           5362

      280

      aaatgtattt ttatgaccgt aaagaatctg tcagtagaag tctgaaattc gtttaaaaat   5422

      cgactagaat aggctttaac gacaagatgt tttaaagagt acgctctaaa tgtatttttg   5482

      tatttttgtt tgattacgaa gtttaaattt aattgacaaa tgttttaaaa tgagtataat   5542

      aggacttgta accgatttta tttttataaa ggagaaagaa agatgaacaa acttttactt   5602

      ggaacagcct ttataggggc tagcttactg attggtgggg gtgctcatgc agatcaaatg   5662

      tttatcgttt gtataatcat aatactggtg agcactctat acaactagtg ggacaccaaa   5722

      agaatgctaa tgtaagtgcg ggttggactt atgaaggtgt cggttggatc gcaccaacaa   5782

      caagttcaag cccagtttac cgtgtgtaca atccaaatgc attattacac aaaaagcaag   5842

      tatgaagccc aaagtttagt aaataagggt tggaaatggg ataataacgg aaaggcggtc   5902

      ttctattctg gaggttctca agccgtatat gtcgcttata atcccaatgc acaatctggc   5962

      gctcacaatt acacggaaag tagctttgag caaaatagct tattgaatac tggttggaaa   6022

      tatggggcag tagcttggta cgggattgga gtaaaaaacg aaatgttaaa cattgctcaa   6082

      attgttagtg gtaatttttc tagtattgtt ggaacttgga aagatacttc tggaaatatg   6142

      cttgaaatta atgcaatggg aaatcttact ttaatatgga aggggcaaa gaatcaaacc    6202

      tttgaacttg gcgcaggtca acaatttaat ggaactgcag atattgcctt aaaaaatgga   6262

      gagatttccc ctggtagtcc acttaacatt tttgttgtac caacagaagt tgctttccct   6322

      aataataaaa aagtagacga ttcaactggg caacaacgaa tttttgtgaa ttattctggt   6382

      acaagccctc aaatggcgaa tagtatggca gcggtggctt tttttagagt tattccatga   6442

      ttatattaaa gttagaattg aataaaatgt attattaaaa agataatatt atatcacgac   6502
```

                                        7

```
aaggcgacat ctatcaactt taccactggt atggaagtga ccattattac atcaggaaac 6562

gctaaaacgg ttgttttac acccgtaaaa taaataataa aataatgtgn aattactgac 6622

agcattttgt cagtaatttt ttttatcaaa atcacacaaa aatgttcgtt gacgaacaaa 6682

aaaaactatg ttataataat tcgtatgcga actaaaaaag aagcgattgg ccgactttta 6742

aaagtagcca gcaaccaaat gtctcgagaa tttgataatt ttgcagctca acttgatttg 6802

acaggtcagc aaatgtcaat tttagatttt cttggaaatc aaagcgaaga aggttcagga 6862

aaagaaatta gtcagacgat gattgaatta gaatttaata tccgacgttc aacaacgacg 6922

gaaattttac agcgcatgga aaagcggctt ttaattaatc gaagaacaag cctgaccgat 6982

gcccgccaaa aatcagttga attaactgaa gaagggaaaa gatatttacc tgaaatcagg 7042

gcttatatcc aagcacataa taaaaaagct tggcgtaatc atggtcatag ctgtttncct 7102

ggttaggngg gccannnnnn nnnnnnnnnnnn nnncnnnnnc nnnnncnnnn cnnnc        7157
```

<210> 4
<211> 279
<212> PRT
<213> Lactococcus lactis

<400> 4

Met	Thr	Tyr	Ala	Asp	Gln	Val	Phe	Lys	Gln	Asn	Ile	Gln	Asn	Ile	Leu
1				5					10					15	

```
Met Thr Tyr Ala Asp Gln Val Phe Lys Gln Asn Ile Gln Asn Ile Leu
1               5                   10                  15
Asp Asn Gly Val Phe Ser Glu Asn Ala Arg Pro Lys Tyr Lys Asp Gly
            20                  25                  30
Gln Met Ala Asn Ser Lys Tyr Val Thr Gly Ser Phe Val Thr Tyr Asp
        35                  40                  45
Leu Gln Lys Gly Glu Phe Pro Ile Thr Thr Leu Arg Pro Ile Pro Ile
    50                  55                  60
Lys Ser Ala Ile Lys Glu Leu Met Trp Ile Tyr Gln Asp Gln Thr Ser
65                  70                  75                  80
Glu Leu Ser Val Leu Glu Glu Lys Tyr Gly Val Lys Tyr Trp Gly Glu
                85                  90                  95
Trp Gly Ile Gly Asp Gly Thr Ile Gly Gln Arg Tyr Gly Ala Thr Val
                100                 105                 110
Lys Lys Tyr Asn Ile Ile Gly Lys Leu Leu Glu Gly Leu Ala Lys Asn
            115                 120                 125
Pro Trp Asn Arg Arg Asn Ile Ile Asn Leu Trp Gln Tyr Glu Asp Phe
            130                 135                 140
```

8

```
Glu Glu Thr Glu Gly Leu Leu Pro Cys Ala Phe Gln Thr Met Phe Asp
145             150             155             160
Val Arg Arg Glu Lys Asp Gly Gln Ile Tyr Leu Asp Ala Thr Leu Ile
            165             170             175
Gln Arg Ser Asn Asp Met Leu Val Ala His His Ile Asn Ala Met Gln
            180             185             190
Tyr Val Ala Leu Gln Met Met Ile Ala Lys His Phe Ser Trp Lys Val
            195             200             205
Gly Lys Phe Phe Tyr Phe Val Asn Asn Leu His Ile Tyr Asp Asn Gln
            210             215             220
Phe Glu Gln Ala Asn Glu Leu Met Lys Arg Thr Ala Ser Glu Lys Glu
225             230             235             240
Pro Arg Leu Val Leu Asn Val Pro Asp Gly Thr Asn Phe Phe Asp Ile
            245             250             255
Lys Pro Glu Asp Phe Glu Leu Val Asp Tyr Glu Pro Val Lys Pro Gln
            260             265             270
Leu Lys Phe Asp Leu Ala Ile
            275
```

9

Abstract

The invention relates to a recombinant *Lactococcus* strain, with environmentally limited growth and viability. More particularly, it relates to a recombinant *Lactococcus* that can only survive in a medium, where well-defined medium compounds are present. A preferred embodiment is a *Lactococcus* that may only survive in a host organism, where said medium compounds are present, but cannot survive outside the host organism in absence of said medium compounds.

5

Figure 1

Thy A locus (7157 bps)

Figure 2

1 thyA promotor — thyA ATG — usp45-hIL-10

2 thyA promotor — thyA ATG — P1 promotor-T7 RBS — usp45-hIL-10

3 thyA promotor — P1 promotor-T7 RBS — usp45-hIL-10

4 P1 promotor-T7 RBS — usp45-hIL-10